Direct Answer to Your Question
There is no direct evidence comparing outcomes when patients switch from zolpidem (Ambien) to suvorexant (Belsomra), so a specific percentage of benefit cannot be stated. However, based on available data, I can provide you with what we know about each medication's efficacy and the limited switching data available.
What the Evidence Actually Shows
Individual Drug Efficacy vs. Placebo
According to the 2017 AASM Clinical Practice Guideline 1:
Zolpidem (Ambien) performance:
- Total sleep time: 29 minutes longer than placebo (95% CI: 11-47 min)
- Wake after sleep onset: 25 minutes less than placebo (95% CI: 18-33 min)
- Quality of sleep: Moderate improvement vs. placebo
Suvorexant (Belsomra) performance:
- Total sleep time: Only 10 minutes longer than placebo (95% CI: 2-19 min)
- Wake after sleep onset: 16-28 minutes less than placebo (95% CI: 7-43 min)
- Quality of sleep: Not reported
The Critical Problem with Switching
Zolpidem appears objectively superior to suvorexant for total sleep time improvement - nearly 3 times better (29 vs 10 minutes). Both medications have similar effects on wake after sleep onset, but zolpidem also demonstrates moderate improvement in subjective sleep quality while suvorexant's quality data wasn't even reported 1.
The Only Direct Switching Study Available
One retrospective study 2 examined 119 patients who switched from benzodiazepine receptor agonists (BzRAs, which includes zolpidem) to suvorexant versus 109 who added suvorexant:
- Switching group had lower discontinuation rates (better tolerability)
- Add-on group had 2.7 times higher odds of discontinuation (95% CI: 1.5-5.0)
- Oversedation was the main problem in the add-on group (22.0% vs 7.6%, p<0.002)
However, this study does NOT tell us what percentage actually benefited from the switch - it only tells us that switching was better tolerated than adding suvorexant on top of existing medication.
Clinical Reality: What This Means for Practice
If you're considering switching a patient from zolpidem to suvorexant, you should expect:
Potentially less total sleep time improvement - The objective data shows suvorexant provides only about one-third the sleep time benefit of zolpidem (10 vs 29 minutes)
Similar sleep maintenance effects - Both reduce wake after sleep onset by roughly 20-25 minutes
Unknown subjective benefit - Suvorexant lacks quality of sleep data in the guideline analysis
Better safety profile with suvorexant - No evidence of daytime residual effects or withdrawal symptoms 1, whereas zolpidem carries risks of complex sleep behaviors, next-day impairment, and withdrawal effects 3
The Honest Answer
You cannot state a percentage of patients who will benefit from switching because this specific comparison has never been properly studied. The one retrospective study 2 only examined tolerability, not efficacy outcomes.
What you CAN say: If switching is being considered for safety reasons (concerns about zolpidem's complex sleep behaviors, abuse potential, or withdrawal), then switching to suvorexant is reasonable, but patients should be counseled that they may experience less robust improvement in total sleep time based on the comparative placebo-controlled data.
The switching study suggests better tolerability when switching rather than adding on 2, but this doesn't tell us about actual sleep improvement outcomes.
Key Caveats
- Both medications received only WEAK recommendations from AASM 1, reflecting low-quality evidence overall
- The guideline data compares each drug to placebo, not to each other
- Individual patient response varies considerably
- Non-pharmacological interventions (CBT-I) should be considered alongside or instead of medication switching 4